Key Points Eli Lilly's high valuation could limit the stock's future returns. Viking Therapeutics is a much smaller company, and it has a promising GLP-1 asset in VK2735. Encouraging data around VK2735 recently gave the stock a big boost. 10 stocks we like better than Viking Therapeutics › Investing in a top company can offer safety and stability, but oftentimes, the potential upside can also be limited. Take Eli Lilly (NYSE:LLY) as a prime example. It's a leader in the GLP-1 space and a top healthcare company, with a market cap of more than $1 trillion. It's generated impressive returns totaling more than 400% in five years, but with a much higher valuation, it may not perform nearly as well over the next five years.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.